New Centrum® VitaMints® offer a refreshingly new way to take a multivitamin

PfizerPfizer Consumer Healthcare has announced the launch of Centrum®VitaMints®, a great-tasting and easy-to-take multivitamin that offers consumers the essential nutrients they can enjoy like a mint, from Centrum®, a brand they know and trust.

"Americans want to live well - they want to eat right and exercise often - however they are often short on the time needed to support an active, healthy lifestyle," said Bahar Takhtehchian, lifestyle and wellness expert. "By offering a multivitamin in a flavor many consumers love, Centrum® VitaMints® give consumers an on-the-go option they enjoy like a mint that helps support energy, immunity and metabolism."

Centrum® VitaMints® is a refreshing and complete multivitamin that provides a more enjoyable experience for consumers to get essential nutrients, and joins other Centrum products to form one of the most comprehensive lines of multivitamins on the market.

"Pfizer Consumer Healthcare is committed to bringing a range of exciting new Centrum multivitamin formulas to market that seamlessly fit into Americans' everyday lives, including Centrum® VitaMints®, a surprisingly and refreshing mint tasting multivitamin that breaks through in a category traditionally known for tablets and gummies," said Robert Uccardi, Director for Centrum, Pfizer Consumer Healthcare.

Centrum® VitaMints® in Cool Mint flavor is intended for adults, and includes such key nutrients as Vitamins A, C, D and E, amongst others. Serving size is two minty chewables daily which can be taken with or without food or water. When it comes to any consumer health product, consumers should always read and follow the directions on the product label, including the recommended daily servings.

Available at major retailers nationwide and online, Centrum® VitaMints® is sold in 60- and 120-count bottles.

It is important to note, dietary supplements are not intended to diagnose, treat, cure or prevent any disease but rather help consumers fill daily dietary gaps.

About Centrum®
With over 35 years of nutritional science expertise, Centrum® multivitamins remain the multivitamin chosen for multiple landmark studies on long-term health benefits and continue to be the most-clinically studied, most-preferred and most-doctor and pharmacist recommended multivitamin brand in America. Centrum® is a complete multivitamin that delivers a combination of essential vitamins and minerals that help support overall health and well-being. Centrum® multivitamins support multiple health benefits such as energy, immunity, heart health, bone health, eye and skin health. To see what nutrients are inside Centrum®, and learn more about our product formulations, please visitwww.Centrum.com (link is external).

Pfizer Inc.: Working together for a healthier world™
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.

Most Popular Now

GSK reaches agreement with Novartis to acquire ful…

GlaxoSmithKline plc (LSE/NYSE: GSK) today announces that it has reached an agreement with Novartis for the buyout of Novartis' 36.5% stake in their Consumer Healthcare Jo...

Canadian neuroscientists say daily ibuprofen can p…

A Vancouver-based research team led by Canada's most cited neuroscientist, Dr. Patrick McGeer, has successfully carried out studies suggesting that, if started early enou...

First proof a synthesized antibiotic is capable of…

A "game changing" new antibiotic which is capable of killing superbugs has been successfully synthesised and used to treat an infection for the first time - and could lea...

Merck partners with Medisafe to help improve medic…

Merck, a leading science and technology company, today announced a new collaboration with US-based Medisafe to help its cardiometabolic patients better manage medication ...

Phase III data in The Lancet show Novartis siponim…

Novartis today announced that the full results from the Phase III EXPAND study of oral, once-daily siponimod (BAF312) in secondary progressive multiple sclerosis (SPMS) w...

Taking a standard prostate cancer drug with food b…

By taking a high-cost drug with a low-fat meal - instead of on an empty stomach, as prescribed - prostate cancer patients could decrease their daily dose, prevent digesti...

North and south cooperation to combat tuberculosis

Tuberculosis can be cured and could be eradicated. For this to happen, however, patients have to receive the right treatment. Researchers at the Makerere University and t...

New immunotherapy for lung cancer shows promise of…

In a groundbreaking development, results from a recent clinical trial to treat lung cancer show that a novel immunotherapy combination is surprisingly effective at contro...

Boehringer Ingelheim and OSE Immunotherapeutics an…

Boehringer Ingelheim and OSE Immunotherapeutics, a biotechnology company focused on the development of innovative immunotherapies, have announced a collaboration and excl...

Personalized tumor vaccine shows promise in pilot …

A new type of cancer vaccine has yielded promising results in an initial clinical trial conducted at the Perelman School of Medicine at the University of Pennsylvania and...

Lokelma approved in the EU for the treatment of ad…

AstraZeneca today announced that the European Commission has granted marketing authorisation for Lokelma (formerly ZS-9, sodium zirconium cyclosilicate) for the treatment...

New targeted therapy schedule could keep melanoma …

Skin melanoma, a particularly insidious cancer, accounts for the vast majority skin cancer deaths and is one of the most common cancers in people under 30. Treatment for ...